Prostate cancer is one of these diseases, and particularly in patients with its advanced form, the lack of AR expression—either constitutive or induced in AR-positive cells by paracrine IL-1β signaling—might be compounded by the functional inactivation of the AR by ADT/ARIs. Here, IL1B is linked to prostate carcinoma.